[1]倪 峥,彭为红.达比加群酯治疗房颤合并急性冠脉综合征的疗效及对患者预后的影响[J].医学信息,2024,37(17):117-119123.[doi:10.3969/j.issn.1006-1959.2024.17.024]
　NI Zheng,PENG Wei-hong.Efficacy of Dabigatran Etexilate in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome and its Effect on the Prognosis of Patients[J].Journal of Medical Information,2024,37(17):117-119123.[doi:10.3969/j.issn.1006-1959.2024.17.024]
点击复制

达比加群酯治疗房颤合并急性冠脉综合征的疗效及对患者预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年17期
页码:
117-119123
栏目:
论著
出版日期:
2024-09-01

文章信息/Info

Title:
Efficacy of Dabigatran Etexilate in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome and its Effect on the Prognosis of Patients
文章编号:
1006-1959（2024）17-0117-04
作者:
倪 峥; 彭为红
安福县人民医院内二科，江西 安福 343200
Author(s):
NI Zheng; PENG Wei-hong
The Second Department of Internal Medicine,Anfu County People’s Hospital,Anfu 343200,Jiangxi,China
关键词:
达比加群酯; 房颤; 急性冠脉综合征; 凝血功能
Keywords:
Dabigatran etexilate; Atrial fibrillation; Acute coronary syndrome; Blood coagulation function
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2024.17.024
文献标志码:
A
摘要:
目的 观察达比加群酯治疗房颤合并急性冠脉综合征的疗效及对患者预后的影响。方法 选取2021年1月-2023年3月我院诊治的62例房颤合并急性冠脉综合征患者为研究对象，采用随机数字表法分为对照组和观察组，各组31例。对照组采用常规治疗，观察组在对照组基础上联合应用达比加群酯治疗，比较两组临床疗效、并发症发生率、凝血功能指标［凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、血浆凝血酶时间（TT）］以及不良反应发生率。结果 观察组治疗总有效率为93.55%，高于对照组的80.65%（P＜0.05）；观察组并发症发生率为9.68%，低于对照组的22.58%（P＜0.05）；两组治疗后PT、APTT、TT均大于治疗前，且观察组大于对照组（P＜0.05）；观察组不良反应发生率为6.45%，与对照组的9.68%比较，差异无统计学意义（P＞0.05）。结论 达比加群酯治疗房颤合并急性冠脉综合征的临床疗效确切，可改善患者预后、凝血功能指标，有效降低并发症发生率，且未增加不良反应发生率，可作为临床治疗房颤合并急性冠脉综合征的有效药物。
Abstract:
Objective To observe the efficacy of dabigatran etexilate in the treatment of atrial fibrillation complicated with acute coronary syndrome and its effect on the prognosis of patients.Methods A total of 62 patients with atrial fibrillation complicated with acute coronary syndrome who were treated in our hospital from January 2021 to March 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 31 patients in each group. The control group was treated with conventional therapy, and the observation group was treated with dabigatran etexilate on the basis of the control group. The clinical efficacy, complication rate, coagulation function indexes [prothrombin time (PT), activated partial thromboplastin time (APTT), plasma thrombin time (TT)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.55%, which was higher than 80.65% in the control group (P<0.05). The incidence of complications in the observation group was 9.68%, which was lower than 22.58% in the control group (P<0.05). After treatment, PT, APTT and TT in the two groups were higher than those before treatment, and those in the observation group were higher than the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.45%, which was compared with 9.68% in the control group, the difference was not statistically significant (P>0.05).Conclusion Dabigatran etexilate has a definite clinical effect in the treatment of atrial fibrillation complicated with acute coronary syndrome. It can improve the prognosis and coagulation function indexes of patients, effectively reduce the incidence of complications, and does not increase the incidence of adverse reactions. Thus, it can be used as an effective drug for clinical treatment of atrial fibrillation complicated with acute coronary syndrome.

参考文献/References:

[1]周芃,陈丰毅,孙运.达比加群酯胶囊和华法林钠片对老年持续性房颤患者血清Ⅰ型胶原代谢标志物的影响比较[J].中国医学工程,2018,26(11):68-70.[2]白颖,王建旗,史旭波,等.心房颤动合并急性冠状动脉综合征患者抗凝治疗现状调查[J].中国医药,2021,16(8):1130-1134.[3]王进华,汪庆玲,黄春燕.冠心病心力衰竭患者心房颤动的危险因素分析[J].内科急危重症杂志,2019,25(6):467-469.[4]魏望江.青年男性早发急性冠脉综合征的相关因素[J].心脏杂志,2019,31(1):31-33.[5]王宇彬,刘庆荣,吴永健.老年冠心病合并心房颤动患者的左心耳封堵治疗[J].中国医刊,2020,55(1):11-14.[6]Ako J,Okumura K,Nakao K,et al.Dual Anti-Thrombotic Therapy With Dabigatran After Percutaneous Coronary Intervention in Atrial Fibrillation-Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial[J].Circ J,2019,83(2):327-333.[7]王葛,赵力,张博阳,等.心功能对非瓣膜性心房颤动合并冠状动脉支架植入患者缺血性脑卒中及死亡风险的影响[J].中国全科医学,2019,22(10):1176-1181. [8]孙雪林,姜毅,王春艳,等.达比加群酯抗凝治疗对非瓣膜性心房颤动患者血管功能的影响[J].中国临床研究,2020,33(3):320-323.[9]周元,许邦龙,高峰.心房颤动合并冠心病冠状动脉介入治疗术后达比加群酯 抗凝治疗的有效性及安全性研究[J].安徽医药,2019,23(4):657-661. [10]张雪松.达比加群酯治疗老年非瓣膜性心房颤动患者血栓栓塞的效果观察[J].慢性病学杂志,2019(12):1792-1794,1798.[11]刘小平,许心元,冯玉宝,等.阻塞性睡眠呼吸暂停与急性冠状动脉综合征关系的研究进展[J].中华老年心脑血管病杂志,2022,24(11):1224-1226.[12]张蕾,胡波,彭奇彪.替格瑞洛联合速效救心丸治疗急性冠状动脉综合征的临床疗效及药学动力研究[J].中国处方药,2023,21(2):114-116.[13]吕雄胜,梅建华,陈小英.华法林对老年非瓣膜病合并房颤患者心功能、血小板活化及疗效的影响[J].中国老年学杂志,2019,39(7):1552-1554.[14]张瑜,王红丽.达比加群酯或华法林治疗高龄非瓣膜性心房颤动合并射血分数下降性心力衰竭患者栓塞事件及出血事件发生率对比研究[J].检验医学与临床,2020,17(11):1602-1604.[15]刘慧慧,李小明,马英.利伐沙班与达比加群酯对心力衰竭合并心房颤动起搏器植入术后囊袋出血及血栓栓塞事件影响研究[J].创伤与急危重病医学,2023,11(2):130-131.[16]范孝英.达比加群酯和利伐沙班在非瓣膜性心房颤动患者抗凝治疗中的临床应用效果[J].实用医技杂志,2020,27(8):1079-1081.[17]施珍,缪培智.达比加群酯对老年持续性房颤合并冠心病患者疗效及对凝血指标、安全性的影响[J].血栓与止血学,2021,27(3):406-408.[18]程勇,袁清茹.达比加群酯胶囊联合复方丹参滴丸在非瓣膜性心房颤动患者抗凝治疗中的应用分析[J].内科,2021,16(2):200-203.[19]邢宇,栗印军.利伐沙班、达比加群酯和华法林用于高龄非瓣膜性房颤病人抗凝治疗的有效性和安全性对比研究[J].中西医结合心脑血管病杂志,2019,17(3):411-413.[20]孙小强,李姮,张香玲,等.达比加群酯联合替格瑞洛对老年心房颤动合并不稳定型心绞痛患者的有效性及安全性研究[J].中国全科医学,2018,21(31):3841-3845.

相似文献/References:

[1]李 燕,王 英.冷冻球囊介入术中并发急性心包填塞的1例抢救护理[J].医学信息,2018,31(08):174.[doi:10.3969/j.issn.1006-1959.2018.08.063]
　LI Yan,WANG Ying.Emergency Nursing Care of One Case of Acute Pericardial Tamponade during Cryopreservation Balloon Intervention[J].Journal of Medical Information,2018,31(17):174.[doi:10.3969/j.issn.1006-1959.2018.08.063]
[2]肖智谦.阵发性室上性心动过速、房颤、胸痛1例[J].医学信息,2018,31(12):190.[doi:10.3969/j.issn.1006-1959.2018.12.063]
　XIAO Zhi-qian.Paroxysmal Supraventricular Tachycardia,Atrial Fibrillation and Chest Pain in 1 Case[J].Journal of Medical Information,2018,31(17):190.[doi:10.3969/j.issn.1006-1959.2018.12.063]
[3]周井铎,田康爱,孟 震,等.急性脾肾梗死伴房颤1例并文献复习[J].医学信息,2018,31(15):191.[doi:10.3969/j.issn.1006-1959.2018.15.066]
[4]张文波,杨玉雯.希氏束起搏在慢性心力衰竭患者中的应用[J].医学信息,2019,32(10):41.[doi:10.3969/j.issn.1006-1959.2019.10.015]
　ZHANG Wen-bo,YANG Yu-wen.Application of His Bundle Pacing in Patients with Chronic Heart Failure[J].Journal of Medical Information,2019,32(17):41.[doi:10.3969/j.issn.1006-1959.2019.10.015]
[5]吴小燕,刘 杰,刘文锋,等.稳定性冠心病合并心房颤动患者抗栓策略的Meta分析[J].医学信息,2020,33(03):82.[doi:10.3969/j.issn.1006-1959.2020.03.024]
　WU Xiao-yan,LIU Jie,LIU Wen-feng,et al.Meta-analysis of Antithrombotic Strategies for Stable Coronary Heart Disease with Atrial Fibrillation[J].Journal of Medical Information,2020,33(17):82.[doi:10.3969/j.issn.1006-1959.2020.03.024]
[6]甄秀丽,冯国鹏.房颤合并冠心病患者冠脉支架植入术后二联和三联抗凝治疗的效果比较[J].医学信息,2021,34(03):162.[doi:10.3969/j.issn.1006-1959.2021.03.046]
　ZHEN Xiu-li,FENG Guo-peng.Comparison of the Effects of Dual and Triple Anticoagulation Therapy in Patients with Atrial Fibrillation and Coronary Heart Disease After Coronary Stent Implantation[J].Journal of Medical Information,2021,34(17):162.[doi:10.3969/j.issn.1006-1959.2021.03.046]
[7]张 凯,魏 昕,丁 盟,等.老年房颤患者非心脏手术围术期心脑血管事件的危险因素分析[J].医学信息,2021,34(06):122.[doi:10.3969/j.issn.1006-1959.2021.06.031]
　ZHANG Kai,WEI Xin,DING Meng,et al.Analysis of Risk Factors for Perioperative Cardiovascular and Cerebrovascular Events in Elderly Patients with Atrial Fibrillation[J].Journal of Medical Information,2021,34(17):122.[doi:10.3969/j.issn.1006-1959.2021.06.031]
[8]章 胜,王昌会,方 浩,等.非瓣膜病房颤患者左心耳血栓形成的预测因素[J].医学信息,2021,34(18):84.[doi:10.3969/j.issn.1006-1959.2021.18.022]
　ZHANG Sheng,WANG Chang-hui,FANG Hao,et al.Predictive Factors of Left Atrial Appendage Thrombosis in Patients with Non-valvular Atrial Fibrillation[J].Journal of Medical Information,2021,34(17):84.[doi:10.3969/j.issn.1006-1959.2021.18.022]
[9]刘东庭.心电散点图鉴别诊断房颤伴宽QRS波心动过速的临床应用价值[J].医学信息,2022,35(11):157.[doi:10.3969/j.issn.1006-1959.2022.11.042]
　LIU Dong-ting.Clinical Value of ECG Scatter Plot in Differential Diagnosis of Atrial Fibrillation with Wide QRS Tachycardia[J].Journal of Medical Information,2022,35(17):157.[doi:10.3969/j.issn.1006-1959.2022.11.042]

更新日期/Last Update: 1900-01-01